Study: Xience V outperforms bare-metal, first-generation stents

06/17/2009 | Forbes

In a six-month follow-up study, Dutch cardiologists found that patients who received Abbott Vascular's Xience V everolimus-eluting stent were less likely to die or experience heart attacks or artery blockage than those who received bare-metal stents or first-generation drug-coated stents. Although the findings are "reassuring," large-scale studies on the device are still needed, an interventional cardiologist said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA